Indeed, previous studies showed that suppression of IGF-1R decreases ABCC2 expression and promoted drug sensitivity in human colon cancer cells [74], and that IGF-1 increased the expression of ABCC1, ABCC2, and ABCC3 in both leukemia cells and ovarian cancer cells [73,75]. Here, ABCC2 is linked to ovarian carcinoma.